Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
Moleculin Biotech, Inc. (MBRX)
Last moleculin biotech, inc. earnings: 8/16 05:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
moleculin.com/investors
Company Research
Source: GlobeNewswire
Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication Significant tumor volume reduction across multiple PDAC models, including orthotopic human and syngeneic systems (p Significantly higher tumor and pancreatic tissue accumulation than doxorubicin (p Induced infiltration of CD8+ and CD4+ T cells, suggesting potential to convert immunologically “cold” pancreatic tumors into responders and supporting future combinations with checkpoint and KRAS inhibitors Continues to demonstrate the absence of cardiotoxicity, a well-documented limitation of conventional anthracyclines such as doxorubicin HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 highlighting
Show less
Read more
Impact Snapshot
Event Time:
MBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBRX alerts
High impacting Moleculin Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
MBRX
News
- Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026 [Yahoo! Finance]Yahoo! Finance
- Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual MeetingGlobeNewswire
- Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic ProfileGlobeNewswire
- Moleculin Biotech files to sell 6.37M shares of common stock for holders [Seeking Alpha]Seeking Alpha
MBRX
Analyst Actions
- 3/24/26 - HC Wainwright
MBRX
Sec Filings
- 4/23/26 - Form 8-K
- 4/15/26 - Form 8-K
- 4/15/26 - Form EFFECT
- MBRX's page on the SEC website